High rates of complete remission reported in patients with advanced blood cancers in preliminary results from ongoing immunotherapy trial
Dec. 7, 2015
| By Susan Keown / Fred Hutch News Service
Many patients with late-stage blood cancers receiving an experimental T-cell therapy went into complete remission, according to preliminary research results from a Fred Hutchinson Cancer Research Center trial presented this week at the annual meeting of the American Society of Hematology.
Immunotherapy a key topic at sold-out discussion on the role of biotech in Seattle
May 7, 2015
| By Bill Briggs / Fred Hutch News Service
The word “cure” has long been overused, but the promise of immunotherapy as an anti-cancer weapon means it’s indeed the right time to start using it, said Dr. D. Gary Gilliland, president and director of Fred Hutch, at an Xconomy Forum held at the Hutch on Wednesday.
Fred Hutch, Memorial Sloan-Kettering and Seattle Children’s Research Institute join to launch Juno Therapeutics
Dec. 3, 2013
| By Deborah Bach
Fred Hutch is advancing its legacy in immunotherapy by means of a new Seattle biotechnology company -- Juno Therapeutics -- that is a unique collaboration among scientists at the Hutch, Memorial Sloan-Kettering Cancer Center in New York and Seattle Children’s Research Institute.